Table of Contents

• What is Benzydamine Hydrochloride?
• How Does It Work?
• Medical Uses
• Formulations and Application
• Effectiveness
• Side Effects
• Precautions
• Comparison with Other Treatments
• Special Applications

What is Benzydamine Hydrochloride?

Benzydamine hydrochloride is a non-steroidal anti-inflammatory drug (NSAID) with analgesic (pain-relieving), anti-inflammatory, and local anesthetic properties. It’s primarily used for the relief of inflammatory conditions of the mouth and throat^[1]. This medication is available in various formulations including oral rinses, sprays, lozenges, and gels. Some common brand names for benzydamine hydrochloride include Difflam, Tantum Verde, and Andolex^[2].

How Does It Work?

Benzydamine’s effectiveness comes from its multiple mechanisms of action:

• It reduces the production of pro-inflammatory substances like TNF-α, IL-1β, and prostaglandins^[3]
• It acts as an antioxidant by neutralizing reactive oxygen species (ROS)^[3]
• It inhibits interactions between white blood cells and the lining of blood vessels, decreasing neutrophil degranulation^[3]
• It helps reduce histamine-induced vasodilation and vascular permeability^[3]
• It provides local anesthetic effects to temporarily relieve pain^[2]

These combined actions make benzydamine particularly useful for treating inflammatory conditions that cause pain and discomfort in the mouth and throat.

Medical Uses

Benzydamine hydrochloride is used to treat various conditions affecting the mouth and throat:

Sore Throat

Benzydamine is commonly used to relieve sore throat pain, especially in cases of acute sore throat associated with upper respiratory tract infections like the common cold^[4]. Clinical studies have shown that benzydamine can provide significant pain relief for sore throats, with effects beginning within minutes of application^[5].

Postoperative Sore Throat

Patients who undergo general anesthesia with endotracheal intubation (insertion of a breathing tube) often experience postoperative sore throat (POST). Benzydamine has been shown to be effective in reducing the incidence and severity of POST when applied to the endotracheal tube cuff before intubation^[6] or used as a spray or gargle after the procedure^[7].

Oral Mucositis

Oral mucositis is inflammation and ulceration of the mucous membranes in the mouth, commonly seen in patients undergoing chemotherapy or radiation therapy for cancer. Benzydamine is recommended for the prevention of radiation-induced oral mucositis in patients with head and neck cancer who are receiving moderate doses of radiation therapy^[8]. The 2019 mucositis guidelines confirm benzydamine mouthwash as the only anti-inflammatory agent with evidence in the prevention of oral mucositis to date^[9].

Other Uses

Benzydamine is also used to relieve pain and inflammation associated with:

• Dental procedures and oral surgery^[10]
• Pericoronitis (inflammation around a partially erupted tooth)^[11]
• Pharyngitis (inflammation of the pharynx)^[12]

Formulations and Application

Benzydamine hydrochloride is available in several forms to suit different needs:

Oral Rinse/Mouthwash

The mouthwash formulation (typically 0.15% concentration) is used by rinsing 15 ml in the mouth for 30 seconds to 2 minutes, then expectorating (spitting out). It’s generally recommended to use 2-3 times daily, but not more than 5 times a day^[9].

Spray

Benzydamine spray (typically 0.15% or 0.3% concentration) is designed to be applied directly to the affected area in the mouth or throat. The typical dosage is 4-8 sprays, 2-6 times a day^[5]. The spray formulation is particularly useful when specific areas need to be targeted or when patient cooperation might be limited, such as in the immediate postoperative period^[7].

Lozenges

Benzydamine lozenges (typically 3 mg) are slowly dissolved in the mouth. They provide a sustained release of the medication and are often used 3-6 times daily^[5].

Gel

Benzydamine gel (typically 0.15% concentration) is applied directly to the affected areas of the mouth or gums. It’s particularly useful for localized conditions^[13].

Effectiveness

Onset of Action

One of the advantages of benzydamine is its rapid onset of action. Studies have shown that benzydamine can provide relief from sore throat pain as quickly as 1-2 minutes after application^[5]. In one study comparing benzydamine spray with lozenges, a significant number of patients reported at least a “slight relief” of sore throat within 2 minutes of application^[5].

Duration of Effect

The pain-relieving effects of benzydamine typically last for several hours. The exact duration depends on the formulation used and the individual’s condition^[5].

Clinical Evidence

Multiple clinical trials have demonstrated the effectiveness of benzydamine in various conditions:

• In patients with acute sore throat, benzydamine provided significant pain relief compared to placebo^[4]
• For postoperative sore throat, benzydamine reduced both the incidence and severity when applied to the endotracheal tube cuff or used as a post-procedure gargle^[6][7]
• In radiation-induced oral mucositis, benzydamine has been shown to reduce the severity and duration of mucositis in patients undergoing head and neck radiotherapy^[8][9]

Side Effects

Benzydamine is generally well-tolerated, but some side effects may occur:

Common Side Effects

• Temporary numbness or tingling in the mouth^[2]
• Burning or stinging sensation in the throat^[2][7]
• Dry mouth^[6]
• Bitter taste^[5]

Less Common Side Effects

• Allergic reactions (such as rash, itching)^[2]
• Nausea^[2]
• Cough^[7]
• Throat irritation^[7]

Most side effects are mild and temporary. If you experience persistent or severe side effects, you should consult your healthcare provider.

Precautions

While benzydamine is generally safe for most people, certain precautions should be taken:

Allergies

If you are allergic to benzydamine or other NSAIDs, you should avoid using this medication^[2].

Pregnancy and Breastfeeding

As with many medications, benzydamine should be used during pregnancy or breastfeeding only if the potential benefits outweigh the potential risks. Consult your healthcare provider before using benzydamine if you are pregnant or breastfeeding^[2].

Children

Some formulations of benzydamine are not recommended for children under 12 years of age. Always check the product information or consult a healthcare provider before using benzydamine in children^[2].

Prolonged Use

Benzydamine is generally intended for short-term use. If symptoms persist for more than 7 days, consult your healthcare provider^[5].

Comparison with Other Treatments

Benzydamine vs. Other NSAIDs

Unlike many other NSAIDs, benzydamine is primarily used topically rather than systemically. This means it acts directly at the site of inflammation with minimal absorption into the bloodstream, reducing the risk of systemic side effects associated with other NSAIDs^[3].

In studies comparing benzydamine with other treatments for sore throat and oral mucositis:

• Benzydamine was found to be as effective as aspirin gargle in reducing the incidence and severity of postoperative sore throat^[14]
• In pericoronitis (inflammation around a partially erupted tooth), topical benzydamine was shown to be as effective as oral diclofenac or flurbiprofen in improving pain and quality of life^[11]
• For radiation-induced oral mucositis, benzydamine was compared with aloe vera gel, with both showing effectiveness in reducing pain and inflammation^[13]

Combination Therapies

Benzydamine is sometimes combined with other active ingredients to enhance its effectiveness:

• Benzydamine combined with cetylpyridinium chloride (an antiseptic) provides both anti-inflammatory and antimicrobial effects^[15]
• In some formulations, benzydamine is combined with lidocaine for enhanced local anesthetic effects^[16]
• For gynecological applications, benzydamine has been studied in combination with econazole nitrate (an antifungal agent)^[17]

Special Applications

Endoscopic Procedures

An interesting application of benzydamine is its use during endoscopic procedures, particularly Endoscopic Retrograde Cholangiopancreatography (ERCP). Studies have shown that gargling with benzydamine hydrochloride before ERCP procedures can reduce the amount of sedative medication (propofol) needed during the procedure^[18].

Vaginal Applications

Benzydamine has also been studied for vaginal applications, particularly in combination with antifungal agents like econazole nitrate. These formulations aim to provide both anti-inflammatory and antimycotic effects for vaginal conditions^[17].

Pharyngeal Packing in Surgery

During certain maxillofacial surgeries, a pharyngeal pack moistened with benzydamine hydrochloride and chlorhexidine gluconate has been shown to reduce postoperative throat pain and nausea compared to packs moistened with saline solution^[19].

During the study, participants will have a baseline assessment of how well their salivary glands work, using a special imaging test called scintigraphy and a simple saliva‑collection test. After the radiation course, the same tests are repeated to compare any changes. An additional scan using ultrasound will look at the size and texture of the glands, and questionnaires will evaluate any feelings of dry mouth and overall quality of life. Safety will be monitored by recording any side effects or problems at the injection site.

Table of Contents

• What is R-Azasetron Besilate?
• Medical Condition Targeted
• How It Works
• Clinical Trial Details
• Dosage and Administration
• Potential Benefits
• Eligibility Criteria
• Safety Considerations

What is R-Azasetron Besilate?

R-Azasetron Besilate, also known as SENS-401, is an investigational drug being developed by Sensorion^[1]. It is currently being studied as a potential treatment to prevent hearing loss caused by cisplatin, a commonly used chemotherapy drug^[1]. R-Azasetron Besilate is considered a new chemical entity, which means it’s a newly developed drug that hasn’t been previously approved for medical use^[1].

Medical Condition Targeted

The primary medical condition targeted by R-Azasetron Besilate is cisplatin-induced hearing loss^[1]. Cisplatin is a powerful chemotherapy drug used to treat various types of cancer. However, one of its significant side effects is damage to the inner ear, which can lead to permanent hearing loss. This condition is known as ototoxicity, which refers to the toxic effects of certain medications on the ear, particularly the cochlea or auditory nerve^[1].

How It Works

While the exact mechanism of action is not detailed in the provided information, R-Azasetron Besilate is being investigated for its potential to prevent or reduce the ototoxic effects of cisplatin. The drug is designed to be taken before, during, and after cisplatin treatment to protect the hearing cells in the inner ear from damage^[1].

Clinical Trial Details

R-Azasetron Besilate is currently being studied in a Phase IIa clinical trial^[1]. This is an important stage in drug development where researchers are testing the drug’s effectiveness and safety in a larger group of patients. The trial is described as:

• Multicenter: Conducted at multiple research sites
• Randomized: Participants are randomly assigned to different treatment groups
• Controlled: Includes a control group for comparison
• Open-label: Both researchers and participants know which treatment is being given

The main objective of the trial is to evaluate how effective R-Azasetron Besilate is in preventing hearing loss caused by cisplatin in adults with cancer^[1].

Dosage and Administration

In the clinical trial, R-Azasetron Besilate is being administered as follows^[1]:

• Form: Film-coated tablet
• Route: Oral use (taken by mouth)
• Dose: 43.5 mg twice daily (b.i.d.)
• Duration: Up to 23 weeks
• Schedule: Starting 1 week before cisplatin treatment, continuing throughout chemotherapy (up to 18 weeks), and for 4 weeks after stopping chemotherapy

The maximum daily dose is 87 mg, and the maximum total dose over the treatment period is 14,355 mg^[1].

Potential Benefits

If successful, R-Azasetron Besilate could provide significant benefits to cancer patients receiving cisplatin chemotherapy^[1]:

• Prevention or reduction of hearing loss: This could help maintain patients’ quality of life during and after cancer treatment
• Allowing for optimal cancer treatment: By reducing the risk of hearing loss, patients might be able to receive the full, most effective doses of cisplatin without compromising their hearing

Eligibility Criteria

The clinical trial has specific criteria for who can participate. Some key inclusion criteria are^[1]:

• Adults aged 18 or older
• Diagnosed with cancer requiring cisplatin treatment (at least 70 mg/m² per cycle and a cumulative dose of at least 210 mg/m²)
• Relatively normal hearing at the start of the study
• Life expectancy of at least 6 months

There are also several exclusion criteria, including certain medical conditions and treatments that could interfere with the study results or pose additional risks to participants^[1].

Safety Considerations

As with any investigational drug, there may be unknown risks and side effects. The clinical trial is designed to monitor participants closely for any adverse effects. Some specific safety considerations mentioned in the trial information include^[1]:

• Participants with a history of certain heart conditions or significant ECG abnormalities are excluded
• People with moderate to severe kidney impairment are not eligible
• The trial excludes individuals with a history of certain ear diseases or conditions that could affect hearing

It’s important to note that R-Azasetron Besilate is still in the testing phase, and its safety and effectiveness have not yet been fully established. Patients interested in this treatment should discuss it with their healthcare provider and consider participating in clinical trials if appropriate^[1].

Table of Contents

• What is Metamizole?
• Chronic Pancreatitis: An Overview
• Clinical Trial on Metamizole for Chronic Pancreatitis Pain
• Who Can Participate in the Study?
• How is the Study Designed?
• How Will the Effectiveness be Measured?
• Potential Benefits and Considerations

What is Metamizole?

Metamizole sodium monohydrate, also known as dipyrone monohydrate, is a medication primarily used for pain relief^[1]. It belongs to a class of drugs called pyrazolones and is known for its pain-relieving (analgesic) and fever-reducing (antipyretic) properties. Metamizole is available in various forms, including tablets, and is being studied for its potential in managing chronic pain conditions.

Chronic Pancreatitis: An Overview

Chronic pancreatitis is a long-term inflammation of the pancreas, an organ that plays a crucial role in digestion and blood sugar regulation^[1]. One of the main symptoms of chronic pancreatitis is persistent abdominal pain, which can significantly impact a patient’s quality of life. Managing this pain effectively is a key goal in treating chronic pancreatitis.

Clinical Trial on Metamizole for Chronic Pancreatitis Pain

A clinical trial is currently underway to investigate the effectiveness of metamizole in treating pain associated with chronic pancreatitis^[1]. The main objective of this study is to determine if adding metamizole to current pain management therapies can effectively reduce pain in patients who have been diagnosed with chronic pancreatitis within the last three years.

The study is designed as a multicenter, randomized, double-blind, placebo-controlled trial. This means:

• Multicenter: The study is conducted at multiple medical facilities.
• Randomized: Participants are randomly assigned to either receive metamizole or a placebo.
• Double-blind: Neither the patients nor the researchers know who is receiving metamizole or the placebo.
• Placebo-controlled: Some participants will receive a placebo (a substance with no active medication) to compare the effects with those receiving metamizole.

Who Can Participate in the Study?

The study has specific criteria for who can participate^[1]. These include:

Inclusion Criteria:

• Confirmed diagnosis of chronic pancreatitis
• Experiencing typical abdominal pain for chronic pancreatitis (dull pain in the upper abdomen) with a pain score of 3 or higher on a 0-10 scale, occurring at least 3 days a week for two weeks

Exclusion Criteria:

• Recent endoscopic or surgical intervention (within the last 3 months)
• Planned endoscopic or surgical intervention for chronic pancreatitis within the next 6 weeks
• Using high doses of opioid pain medications (more than 90 morphine milligram equivalents per day)
• Currently using metamizole
• Having any conditions that would make it unsafe to use metamizole
• Diagnosis of pancreatic cancer
• Recent start (less than 6 weeks ago) of certain medications like amitriptyline, pregabalin, or gabapentin

How is the Study Designed?

The study involves an intervention phase where all participants will receive either metamizole or a placebo in addition to their current pain management therapy^[1]. The key points of the study design are:

• Participants will be randomly assigned to either the metamizole group or the placebo group.
• The metamizole group will receive 1000mg of oral metamizole three times daily, in addition to their current pain medication.
• The placebo group will receive a placebo tablet three times daily, in addition to their current pain medication.
• The study will last for 6 weeks, with the intervention phase lasting 4 weeks.

How Will the Effectiveness be Measured?

The study will use several methods to measure how well metamizole works for pain relief^[1]:

• Primary measure: The main measure will be the average daily pain intensity score. Patients will record their pain levels daily using a scale from 0 (no pain) to 10 (worst pain imaginable).
• Secondary measures: These include:
  • Izbicki pain score: A comprehensive pain assessment tool specific to pancreatic diseases
  • The highest daily pain intensity score
  • The number of patients achieving significant pain reduction
  • The number of pain-free days
  • The number of days with acceptable pain levels
  • The total amount of additional pain medication (measured in morphine milligram equivalents) needed
  • Quality of life assessments using standardized questionnaires (PANQOLI and SF-36)
  • Patient satisfaction with the treatment (PGIC – Patient Global Impression of Change)

Potential Benefits and Considerations

If proven effective, metamizole could offer several benefits for patients with chronic pancreatitis^[1]:

• Improved pain management: It may provide better pain relief when added to current treatments.
• Reduced need for strong painkillers: It might help decrease the use of opioid medications, which can have significant side effects.
• Better quality of life: Effective pain management could lead to improved overall well-being and daily functioning.

However, it’s important to note that this is still a research study, and the full effects and potential side effects of metamizole in this context are still being investigated. Patients should always consult with their healthcare providers before considering any new treatments or participating in clinical trials.

Table of Contents

• What is Lidocaine Hydrochloride Monohydrate?
• Medical Uses
• How is it Administered?
• Dosage Information
• Potential Side Effects
• Precautions and Contraindications
• Ongoing Research

What is Lidocaine Hydrochloride Monohydrate?

Lidocaine Hydrochloride Monohydrate is a medication that belongs to a class of drugs called local anesthetics^[1]. It works by blocking nerve signals in your body, which helps to reduce pain and discomfort in specific areas. This drug is commonly known by its shorter name, lidocaine. It’s important to note that lidocaine is different from general anesthetics, which make you unconscious during surgery. Instead, lidocaine keeps you awake but numbs a particular part of your body.

Medical Uses

Lidocaine has several important medical uses:

• Local anesthesia: It’s used to numb specific areas of the body during minor surgical procedures, dental work, or when inserting medical devices^[2].
• Pain relief: Lidocaine can help manage various types of pain, including post-surgical pain and certain chronic pain conditions.
• Cardiac arrhythmias: In some cases, lidocaine is used to treat irregular heartbeats^[2].
• Gastrointestinal issues: Research is being conducted on the use of oral lidocaine to prevent gastrointestinal disturbances in patients after abdominal surgery^[3].

How is it Administered?

Lidocaine can be administered in several ways, depending on its intended use:

• Injection: For local anesthesia, lidocaine is often injected directly into the area that needs to be numbed^[4].
• Topical application: It can be applied to the skin as a cream, ointment, or patch for localized pain relief.
• Intravenous (IV) use: In some medical settings, lidocaine may be given through an IV for certain heart conditions or as part of a pain management strategy^[5].
• Oral form: Some research is exploring the use of oral lidocaine for specific conditions, such as preventing gastrointestinal issues after surgery^[3].

Dosage Information

The dosage of lidocaine varies widely depending on its use, the specific formulation, and individual patient factors. For example:

• For local anesthesia, the dose can range from 1 to 5 mg/kg of body weight^[5].
• In research on oral lidocaine for gastrointestinal issues, doses up to 400 mg per day are being studied^[3].

It’s crucial to emphasize that lidocaine should only be administered by or under the supervision of a healthcare professional. They will determine the appropriate dose based on your specific situation, medical history, and other factors.

Potential Side Effects

Like all medications, lidocaine can cause side effects. Most side effects are mild and temporary, but some can be serious. Common side effects may include:

• Numbness or tingling at the application site
• Mild dizziness or lightheadedness
• Nausea
• Vomiting

More serious side effects, which require immediate medical attention, can include:

• Allergic reactions (rash, itching, swelling)
• Severe dizziness or fainting
• Irregular heartbeat
• Seizures
• Difficulty breathing

It’s important to report any unusual symptoms to your healthcare provider promptly^[6].

Precautions and Contraindications

Certain conditions or factors may affect the use of lidocaine:

• Allergies: If you’re allergic to lidocaine or similar local anesthetics, you should not use this medication.
• Liver or kidney disease: These conditions may affect how your body processes lidocaine.
• Heart conditions: Lidocaine can affect heart rhythm, so it should be used with caution in people with certain heart problems.
• Pregnancy and breastfeeding: The safety of lidocaine during pregnancy and breastfeeding should be discussed with a healthcare provider.

Always inform your healthcare provider about all medications you’re taking, including over-the-counter drugs and supplements, as they may interact with lidocaine^[6].

Ongoing Research

Lidocaine is being studied for various potential uses beyond its current applications. Some areas of ongoing research include:

• Gastrointestinal issues: A study is investigating the use of oral lidocaine to prevent gastrointestinal disturbances in patients after abdominal surgery^[3].
• Pain management: Researchers are exploring new ways to use lidocaine for managing different types of pain, including chronic pain conditions.
• Combination therapies: Studies are looking at how lidocaine might work in combination with other medications to enhance pain relief or reduce side effects.

These research efforts aim to expand our understanding of lidocaine’s potential benefits and optimize its use in medical care. However, it’s important to remember that research findings may not immediately translate into new approved uses, and any new applications would need to go through rigorous testing and regulatory approval processes before becoming widely available.

Table of Contents

• Overview of the clinical trials
• Trials in adults with obesity
• Trials in children with obesity
• Trials in healthy volunteers
• Trial in type 2 diabetes
• Main outcomes and what they mean

Overview of the clinical trials

The provided trial data show research on Liraglutide in several groups, mainly people with obesity and children with obesity, plus healthy volunteers and people with type 2 diabetes.^[1][2][3][4] The studies are in Phase 2 and Phase 3, which means they are testing effects in research settings and comparing outcomes in larger groups.^[1][2][3][4] The main goals are to measure changes in body weight, BMI, hunger, stomach activity, and blood sugar control.^[1][2][3][4]

Trials in adults with obesity

One Phase 2 study, NCT2024-513679-42-00, enrolled 255 adults with obesity or overweight and was completed.^[1] It compared multiple dose levels of PF-07976016 against placebo in participants with obesity on a background of liraglutide, and it also included Saxenda as a study treatment listed in the data.^[1] The main outcome was the percent change in body weight at Week 16.^[1]

This study is important because it focuses on whether adding another study medicine can change weight more than placebo in people already receiving liraglutide-based background treatment.^[1] The trial was interventional, which means researchers gave the study treatments and then measured the effects.^[1]

Trials in children with obesity

One Phase 3 study, NCT2023-508504-38-00, is authorised and includes 82 children aged 6 to under 12 years with obesity.^[3] The study compares Liraglutide 3.0 mg once daily with placebo for weight management in this age group.^[3] The main outcome is the relative change in BMI from Week 0 to Week 56.^[3]

This trial is focused on a younger population, so it helps answer whether the study treatment can support weight-related care in children with obesity.^[3] The use of BMI change as the main outcome shows that the trial is measuring growth-related weight patterns over time, not just short-term change.^[3]

Trials in healthy volunteers

Another Phase 3 study, NCT2024-518641-21-00, is authorised and includes 15 healthy volunteers.^[2] It studies the effect of liraglutide on MMC activity, gastrointestinal hormones, hunger ratings, and ad libitum food intake.^[2] The main outcome is to detect changes in MMC activity after administration of liraglutide compared with placebo.^[2]

This type of study does not focus on a disease group alone; instead, it helps researchers observe how the study treatment affects digestive patterns and hunger in people without the target condition.^[2] The trial uses saline as the placebo comparison and measures several body responses at once.^[2]

Trial in type 2 diabetes

The provided data also include a large Phase 3 study, NCT05433584, in 781 adult participants with type 2 diabetes.^[4] In this trial, Liraglutide appears among several treatment options in a study comparing tirzepatide with intensified conventional care.^[4] The main outcome is the change from baseline in HbA1c.^[4]

This study is not only about one medicine, but it still shows that liraglutide is part of the treatment list being studied in people with type 2 diabetes.^[4] HbA1c is a key diabetes measure because it reflects average blood sugar over time.^[4]

Main outcomes and what they mean

Across these trials, the main outcomes are practical measures that matter to patients and researchers.^[1][2][3][4] The obesity studies look at body weight and BMI, which are common ways to track weight change.^[1][3] The healthy volunteer study looks at stomach movement, hunger, and food intake, which helps show how the body responds after treatment.^[2] The diabetes study uses HbA1c, which helps show longer-term blood sugar control.^[4]

The trial data also show different study sizes, from 15 healthy volunteers to 781 people in the diabetes study.^[2][4] This range suggests that the research questions are different: some studies are small and focused on body responses, while others are larger and compare treatment effects in broader patient groups.^[1][2][3][4]

Table of Contents

• What is Human Serum Albumin 5%?
• Medical Uses
• Administration
• Safety Considerations
• Ongoing Research

What is Human Serum Albumin 5%?

Human Serum Albumin 5% (HSA) is a protein-based solution derived from human blood plasma. It is a crucial component in various medical treatments and is often used in combination with other substances for therapeutic purposes^[1].

Medical Uses

Human Serum Albumin 5% has several important medical applications:

• Placebo in Clinical Trials: HSA is often used as a placebo (an inactive substance) in clinical trials to compare the effectiveness of new treatments. This helps researchers determine if a new therapy is truly beneficial^[1].
• Vehicle for Drug Delivery: It serves as a carrier for other medications, helping to distribute them effectively throughout the body^[1].
• Volume Expander: In some medical conditions, HSA can be used to increase blood volume, which is crucial for maintaining proper circulation^[1].

Administration

Human Serum Albumin 5% is typically administered through the following methods:

• Local Injection: In some treatments, HSA is injected directly into the affected area. For example, in clinical trials for vocal fold scarring and Crohn’s disease fistulas, it is injected locally^[1][2].
• Intravenous Infusion: In other cases, HSA may be given through an IV drip, especially when used as a volume expander.

The dosage and administration method can vary depending on the specific medical condition and treatment protocol.

Safety Considerations

While Human Serum Albumin 5% is generally considered safe, there are some important safety considerations:

• Allergic Reactions: Some individuals may be sensitive to human albumin. Patients with known hypersensitivity to human albumin should not receive HSA treatments^[1][2].
• Infection Risk: As HSA is derived from human blood, there is a theoretical risk of viral transmission. However, stringent screening and purification processes are in place to minimize this risk^[1].
• Contraindications: HSA may not be suitable for individuals with certain medical conditions. Always consult with a healthcare provider before starting any new treatment^[1][2].

Ongoing Research

Human Serum Albumin 5% is currently being studied in various clinical trials:

• Vocal Fold Scarring: A study is investigating the use of HSA as part of a placebo treatment for scarred vocal folds. This research aims to compare the effectiveness of new cellular therapies against a placebo containing HSA^[1].
• Crohn’s Disease Fistulas: Another clinical trial is exploring the use of HSA as part of a placebo treatment for complex refractory perianal Crohn’s fistulas. This study compares the efficacy of cellular treatments to a placebo containing HSA^[2].

These ongoing studies highlight the importance of Human Serum Albumin 5% in medical research and its potential to contribute to new treatments for various conditions.

Table of contents

• Trials overview
• Who participated
• What was studied
• Trial phases and study size
• Main endpoints measured
• Safety and reactogenicity
• Study populations and comparators

Trials overview

The trial data show three interventional studies that include GSKVX000000048111 as part of influenza vaccine research.^[1][2][3] These studies were designed to assess immune response and safety in adults and healthy volunteers.^[1][2][3]

Two studies focused on adults 18 years of age and older with influenza, Human as the condition studied.^[1][2] One study focused on healthy younger and older adults and described prevention of influenza infection.^[3]

Who participated

The studies included adults 18 years and older, and one study also included healthy younger and older adults.^[1][2][3] This means the research was not limited to one narrow group, but the exact group depended on the specific trial.^[1][2][3]

All three studies were interventional, which means the researchers gave study vaccines and then measured the results.^[1][2][3]

What was studied

GSKVX000000048111 was studied as part of vaccine groups for influenza, not as a single stand-alone study product.^[1][2][3] The trial records list it with other GSKVX000000 products and with comparator vaccines such as Alpharix, Alpharix-Tetra, and Efluelda, as well as influenza vaccine components described as inactivated split virus or recombinant haemagglutinin.^[1][2][3]

In simple terms, the studies were comparing different influenza vaccine options to see which ones gave the best immune response and acceptable safety results.^[1][2][3]

Trial phases and study size

One study was in Phase 1/2 and two studies were in Phase 2.^[1][2][3] Phase 1/2 studies are early studies that look at safety and the first signs of immune response, while Phase 2 studies look further at safety and how the vaccine performs in a larger group.^[3][1][2]

The reported enrollment was 770 participants in one Phase 2 study, 960 in another Phase 2 study, and 1,272 in the Phase 1/2 study.^[1][2][3] Enrollment means the planned or actual number of people included in the study.^[1][2][3]

Main endpoints measured

The main endpoints were immune response measures and safety measures.^[1][2][3] Endpoints are the main results the researchers plan to measure in a trial.^[1][2][3]

• Antibody titer at Day 29 was measured to see how strong the immune response was after vaccination.^[1][2][3]

• Fold increase in antibody titer from Day 1 to Day 29 showed how much the antibody level rose after the study intervention.^[1][2][3]

• Seroconversion measured whether participants developed a new antibody response after vaccination.^[1][2][3]

• Seroprotection measured whether antibody levels reached a level thought to give protection.^[1][2][3]

The studies also measured changes in antibody levels at Day 1 and Day 29, and in one study also looked at antigen 2 results, not just antigen 1.^[2] This helps researchers compare how the body responds to different vaccine parts.^[2]

Safety and reactogenicity

The studies closely tracked solicited administration site or systemic events, which are expected short-term reactions such as pain where the shot was given or general symptoms like fever.^[1][2]

They also measured unsolicited adverse events within 28 days, serious adverse events within 6 months, adverse events of special interest within 6 months, medically attended adverse events within 6 months, and laboratory abnormalities after dosing.^[1][2] These safety checks help show whether any medical problems happened after vaccination and how often they occurred.^[1][2]

One study also measured shifts from non-clinically significant laboratory values on Day 1 to clinically significant abnormal values on Day 8 and/or Day 29 for hematology and clinical chemistry.^[3] Hematology means blood cell tests, and clinical chemistry means blood tests that check body chemicals and organ function.^[3]

Study populations and comparators

The trial records show that GSKVX000000048111 was studied alongside several other influenza vaccine candidates and licensed comparator vaccines.^[1][2][3] Comparators are other vaccines used for comparison, so researchers can judge whether the study vaccine gives similar or better immune responses and safety results.^[1][2][3]

Because the studies included both completed and authorised trials, the trial program appears to be at different stages of development.^[1][2][3] The main focus across the studies stayed the same: immune response and safety in adults and healthy volunteers.^[1][2][3]

Table of contents

• Trial overview
• Who can participate
• What the trials measure
• Trial phases and status
• Trial summary
• Key patient terms

Trial overview

Clinical trials with GSKVX000000048110 are studying influenza vaccine candidates in adults.^[1] The trial data show studies in adults 18 years and older, healthy younger and older adults, and healthy volunteers for prevention of influenza infection.^[1][2][3]

All listed studies are interventional, which means researchers give a study intervention and then measure the results.^{[1][2][3] The conditions studied are related to human influenza.[1][2][3]}

Who can participate

One study includes adults 18 years of age and older.^[1] Another study includes healthy younger and older adults.^[3] The third study includes healthy volunteers and focuses on prevention of influenza infection.^[3]

These are vaccine studies, so the source data point to people who are well enough to join a vaccination trial rather than people being treated for active influenza illness.^[2][3]

What the trials measure

The main goal is to see how strongly the body makes antibodies after vaccination, also called the humoral immune response.^{[1][2][3] Antibodies are proteins made by the immune system that can help fight infection.}

Researchers measure antibody titer at Day 29, the fold increase from Day 1 to Day 29, seroconversion from Day 1 to Day 29, and seroprotection at Day 1 and Day 29.^{[1][2] In the Phase 1/2 study, they also measure geometric mean titer, geometric mean increase, and antigen 2 responses.[3]}

Safety is also a major focus.^{[1][2][3] The trials record solicited administration site events and systemic events within 7 days, unsolicited adverse events within 28 days, serious adverse events within 6 months, adverse events of special interest within 6 months, medically attended adverse events within 6 months, and laboratory abnormalities after dosing.[1][2][3]}

Trial phases and status

The source data list two Phase 2 studies and one Phase 1/2 study.^{[1][2][3] Phase 1/2 means the study is looking at early safety and also beginning to check immune response in a larger group.}

One Phase 2 study is authorised and has 960 planned participants.^[1] Another Phase 2 study is completed with 770 participants.^[2] The Phase 1/2 study is completed with 1272 participants.^[3]

Trial summary

Across the three studies, GSKVX000000048110 appears in influenza vaccine combinations that are compared with other influenza vaccine options listed in the trial records.^{[1][2][3] The studies are designed to learn whether the vaccine candidates can produce a good immune response and whether they are well tolerated after injection.[1][2][3]}

Because the trials focus on antibodies and safety checks, they are typical vaccine research studies rather than treatment studies for active disease.^[1][2][3]

Key patient terms

• Humoral immune response: the part of the immune response that uses antibodies to help protect the body.^[1][2][3]
• Seroconversion: a change showing that antibody response has risen after vaccination.^[1][2]
• Seroprotection: an antibody level that is thought to give protection.^[1][2]
• Reactogenicity: the short-term reactions that happen after a vaccine, such as local or general symptoms.^[1][2][3]
• Adverse event: any unwanted health problem that happens during a study.^[1][2][3]
• Serious adverse event: a severe health problem that needs close attention.^[1][2][3]

Table of Contents

• What is GOZETOTIDE ALF-18?
• How It Works
• Medical Conditions Being Studied
• Current Clinical Trials
• How GOZETOTIDE ALF-18 is Administered
• Potential Benefits
• Who Can Participate in the Studies?
• Safety Considerations

What is GOZETOTIDE ALF-18?

GOZETOTIDE ALF-18, also known as [18F]PSMA-11 or [18F]PSMA-HBED, is a radiopharmaceutical being studied for its potential in cancer imaging^[1][2]. It’s a special type of drug that contains a small amount of radioactive material, which helps doctors see certain types of cancer cells more clearly on imaging scans.

How It Works

GOZETOTIDE ALF-18 works by targeting a specific protein called Prostate-Specific Membrane Antigen (PSMA). While PSMA is commonly associated with prostate cancer, researchers have found that it’s also present in other types of cancer cells^[1][2]. When injected into the body, GOZETOTIDE ALF-18 attaches to these PSMA proteins, allowing doctors to see cancer cells more clearly on a special type of scan called a PET (Positron Emission Tomography) scan.

Medical Conditions Being Studied

Current clinical trials are investigating the use of GOZETOTIDE ALF-18 in several types of cancer:

• Head and neck squamous cell carcinoma (HNSCC): A type of cancer that starts in the cells lining the mouth, nose, or throat^[1]
• Thyroid carcinoma: Cancer that develops in the thyroid gland^[1]
• Hepatocellular carcinoma (HCC): The most common type of primary liver cancer^[2]

Current Clinical Trials

Two main clinical trials are currently studying GOZETOTIDE ALF-18:

1. A study focusing on advanced thyroid and head and neck cancer^[1]
2. A study on liver cancer (hepatocellular carcinoma)^[2]

These trials aim to evaluate how well GOZETOTIDE ALF-18 can detect cancer cells compared to other imaging methods currently in use.

How GOZETOTIDE ALF-18 is Administered

GOZETOTIDE ALF-18 is given as a solution for injection through an intravenous injection (directly into a vein)^[1][2]. The dose is calculated based on the patient’s weight, with a maximum dose ranging from 2.2 to 4.4 MBq/kg (megabecquerels per kilogram of body weight).

Potential Benefits

The potential benefits of using GOZETOTIDE ALF-18 include:

• More accurate detection of cancer cells^[1][2]
• Improved staging of cancer, which helps determine how far the cancer has spread^[2]
• Better planning for treatment^[2]
• Potential to predict patient outcomes^[2]

Who Can Participate in the Studies?

While specific criteria may vary between studies, general eligibility includes:

• Being 18 years of age or older^[1][2]
• Having a confirmed diagnosis of the specific cancer being studied^[1][2]
• Being willing and able to provide informed consent^[1][2]

Some conditions that may prevent participation include:

• Having other active cancers besides the one being studied^[1][2]
• Being pregnant or breastfeeding^[1][2]
• Having a history of prostate cancer (for the liver cancer study)^[2]

Safety Considerations

As with any medical procedure involving radiation, there are some safety considerations:

• The amount of radiation used is carefully controlled to minimize risks^[1][2]
• Pregnant women are excluded from the studies due to potential risks to the fetus^[1][2]
• The studies are closely monitored by medical professionals to ensure patient safety^[1][2]

It’s important to note that GOZETOTIDE ALF-18 is still being studied, and more research is needed to fully understand its benefits and potential risks. If you’re interested in participating in these studies or learning more about this radiopharmaceutical, speak with your healthcare provider.

Table of Contents

• What is Autologous Adipose Tissue-Derived Stromal Vascular Fraction (ADSVF)?
• Conditions Being Treated with ADSVF
• How ADSVF Works
• How ADSVF is Administered
• Current Clinical Trials
• Safety and Side Effects
• Future Research and Potential

What is Autologous Adipose Tissue-Derived Stromal Vascular Fraction (ADSVF)?

Autologous Adipose Tissue-Derived Stromal Vascular Fraction (ADSVF) is an innovative medical treatment that uses cells from a patient’s own fat tissue. The term “autologous” means the cells come from the patient’s own body, while “adipose tissue” refers to fat tissue. Stromal vascular fraction (SVF) is a complex mixture of cells found within fat tissue, including stem cells, immune cells, and other supportive cells^[1].

Conditions Being Treated with ADSVF

Research is ongoing to explore the potential of ADSVF in treating various medical conditions. Current clinical trials are investigating its use in:

• Urethral stricture: A narrowing of the urethra that can cause difficulty urinating^[2].
• Diabetic foot ulcers: Chronic wounds that occur in people with diabetes^[3].
• Scarred vocal folds: Damage to the vocal cords that can cause voice problems^[4].
• Perianal Crohn’s disease fistulas: Abnormal connections between the intestine and skin near the anus in patients with Crohn’s disease^[5].

How ADSVF Works

ADSVF is believed to work through several mechanisms:

1. Regeneration: The stem cells in ADSVF may help regenerate damaged tissues.
2. Anti-inflammatory effects: ADSVF contains cells that can reduce inflammation in the treated area.
3. Angiogenesis: ADSVF may promote the formation of new blood vessels, improving blood supply to the affected area.
4. Immunomodulation: The cells in ADSVF can help regulate the immune response, potentially beneficial in conditions like Crohn’s disease.

How ADSVF is Administered

The process of ADSVF treatment typically involves:

1. Fat harvesting: A small amount of fat is taken from the patient’s body, usually from the abdomen or thighs.
2. Processing: The fat tissue is processed to isolate the stromal vascular fraction.
3. Injection: The ADSVF is then injected into the affected area. For example:
   • For urethral strictures, it’s injected near the urethra^[2].
   • For diabetic foot ulcers, it’s injected around the wound^[3].
   • For vocal fold scars, it’s injected into the vocal folds^[4].
   • For Crohn’s disease fistulas, it’s injected around the fistula tracts^[5].

Current Clinical Trials

Several clinical trials are currently underway to evaluate the safety and effectiveness of ADSVF for various conditions:

• A study for recurrent urethral stricture, comparing ADSVF injection to standard treatment^[2].
• A trial for diabetic foot ulcers that haven’t responded to standard care^[3].
• An investigation into ADSVF for treating scarred vocal folds and improving voice quality^[4].
• A study on the use of ADSVF combined with microfat for treating perianal fistulas in Crohn’s disease^[5].

Safety and Side Effects

As ADSVF uses the patient’s own cells, the risk of rejection is low. However, potential side effects may include:

• Pain or discomfort at the injection site
• Bruising or swelling
• Infection (though rare)

The ongoing clinical trials are closely monitoring patients for any adverse effects to ensure the safety of this treatment^[2][3][4][5].

Future Research and Potential

ADSVF is an exciting area of research in regenerative medicine. Future studies may explore its use in other conditions and further refine the treatment process. As research progresses, we may gain a better understanding of how factors like the composition of ADSVF and individual patient characteristics affect treatment outcomes^[5].

While ADSVF shows promise, it’s important to note that these treatments are still experimental. Patients should discuss all treatment options with their healthcare providers to determine the best approach for their individual situation.

Table of Contents

• What is SENS-501?
• How Does SENS-501 Work?
• Target Condition: Severe to Profound Hearing Loss
• Clinical Trial Details
• Eligibility Criteria
• Administration and Dosage
• Potential Benefits and Risks
• Future Prospects

What is SENS-501?

SENS-501 is an innovative gene therapy product designed to treat severe to profound hearing loss caused by mutations in the otoferlin gene^[1]. It is currently being studied in a Phase I/II clinical trial to evaluate its safety and effectiveness in children with this specific type of hearing impairment^[2].

The therapy consists of two main components:

• SENS-501-Nter: An adeno-associated viral vector serotype 8 containing the 5′ human otoferlin coding sequence
• SENS-501-Cter: An adeno-associated viral vector serotype 8 containing the 3′ human otoferlin coding sequence

These components work together to deliver the complete otoferlin gene to the inner ear cells^[3].

How Does SENS-501 Work?

SENS-501 is a gene therapy that aims to restore hearing by addressing the underlying genetic cause of otoferlin deficiency^[4]. Here’s how it works:

1. The therapy contains the cDNA sequence of the human otoferlin gene (specifically, isoform 5).
2. It is delivered directly into the cochlea, the part of the inner ear responsible for hearing.
3. Once inside, it aims to restore the expression of the full-length, active human otoferlin protein in the cochlear inner hair cells (IHCs).
4. By repairing the otoferlin deficiency, the therapy seeks to restore the patient’s hearing^[5].

Target Condition: Severe to Profound Hearing Loss

SENS-501 is specifically designed for children with bilateral severe to profound hearing loss due to otoferlin deficiency^[6]. This condition is characterized by:

• Severe to profound hearing loss in both ears
• Caused by mutations in both copies of the otoferlin gene
• Presence of outer hair cell function (indicated by otoacoustic emissions or OAEs)
• Normal cochlear and internal auditory canal structure^[7]

Clinical Trial Details

The ongoing clinical trial for SENS-501 is a Phase I/II study with the following characteristics:

• Trial design: Open-label, dose escalation and expansion study
• Participants: Children aged 6 to 31 months
• Main objectives:
  • Part 1: Assess safety and tolerability of SENS-501
  • Part 2: Evaluate the efficacy of SENS-501
• Secondary objectives: Evaluate the clinical performance, safety, and usability of the SPHYNX Pump and Catheter used for administration^[8]

Eligibility Criteria

To participate in the SENS-501 clinical trial, children must meet specific criteria, including:

• Age between 6 and 31 months at the time of inclusion
• Severe to profound hearing loss confirmed by ABR (Auditory Brainstem Response)
• Biallelic mutation in the otoferlin gene
• Presence of OAEs (Otoacoustic Emissions)
• Normal cochlear and internal auditory canal structure
• Intact vestibular function^[9]

Children with certain conditions, such as prior cochlear implants or participation in other gene therapy trials, are not eligible for this study^[10].

Administration and Dosage

SENS-501 is administered through a unilateral intracochlear injection, meaning it’s injected into one ear. The study is testing two dose levels:

• Low dose: 1.5 E+11 VG SENS-501-Nter + 1.5 E+11 VG SENS-501-Cter
• High dose: 4.5 E+11 VG SENS-501-Nter + 4.5 E+11 VG SENS-501-Cter

The therapy is administered as a single dose using a special delivery system consisting of an infusion pump and an intracochlear catheter^[11].

Potential Benefits and Risks

While SENS-501 shows promise, it’s important to understand that it’s still in the experimental stage. Potential benefits and risks include:

Potential benefits:

• Improvement in hearing thresholds
• Restoration of otoferlin protein function
• Long-term hearing improvement^[12]

Potential risks:

• Adverse reactions to the therapy
• Complications from the intracochlear injection procedure
• Unknown long-term effects of gene therapy^[13]

Future Prospects

If successful, SENS-501 could represent a significant breakthrough in treating genetic causes of hearing loss. The therapy has received orphan drug designation (EU/3/22/2698), indicating its potential to address an unmet medical need^[14].

As research progresses, SENS-501 may offer hope to children with severe hearing loss due to otoferlin gene mutations, potentially improving their quality of life and communication abilities.

Table of Contents

• What is AAVAnc80-hOTOF?
• How Does It Work?
• Who Can Benefit from This Treatment?
• Clinical Trials
• How is AAVAnc80-hOTOF Administered?
• Safety and Efficacy
• Long-Term Follow-Up

What is AAVAnc80-hOTOF?

AAVAnc80-hOTOF is an exciting new gene therapy being developed to treat a specific type of hearing loss called otoferlin gene-mediated hearing loss^[1]. This therapy is designed to help people who have hearing problems because of mutations in their otoferlin gene (OTOF).

How Does It Work?

AAVAnc80-hOTOF uses a special type of virus called AAV (adeno-associated virus) to deliver a healthy copy of the otoferlin gene to the inner ear^[1]. The therapy consists of two parts:

• AAVANC80-5’HOTOF: This is one part of the gene therapy.
• AAVANC80-3’HOTOF: This is the other part of the gene therapy.

Together, these two parts carry the complete instructions for making the otoferlin protein, which is essential for normal hearing^[1].

Who Can Benefit from This Treatment?

This therapy is being developed for people who have profound bilateral sensorineural hearing loss due to mutations in both copies of their otoferlin gene. The current clinical trial is focusing on:

• Children aged 7 to 17 years old for the initial group
• Children aged 2 to 17 years old for later groups^[1]

To be eligible, patients must have confirmed mutations in their OTOF gene and show signs of profound hearing loss, such as no response to loud sounds in hearing tests^[1].

Clinical Trials

AAVAnc80-hOTOF is currently being studied in clinical trials to determine its safety and effectiveness. The main trial is a Phase 1/2 study that aims to:

• Assess the safety and tolerability of different doses of AAVAnc80-hOTOF
• Measure how well the therapy improves hearing^[1]

How is AAVAnc80-hOTOF Administered?

AAVAnc80-hOTOF is given as a one-time treatment directly into the inner ear. This is called an intracochlear administration. The procedure involves:

• A surgical procedure under general anesthesia
• Use of a special delivery device to inject the therapy into the cochlea (the part of the inner ear responsible for hearing)^[1]

Safety and Efficacy

The main goals of the current clinical trial are to evaluate:

• The safety of AAVAnc80-hOTOF, including any side effects
• How well the therapy improves hearing, measured by various hearing tests^[1]

Researchers will be closely monitoring participants for any adverse events and checking their hearing regularly to see if there are improvements.

Long-Term Follow-Up

Because AAVAnc80-hOTOF is a new type of treatment, it’s important to monitor its long-term effects. A separate long-term follow-up study is planned to:

• Evaluate the long-term safety of AAVAnc80-hOTOF, including any late-occurring side effects
• Assess how well the hearing improvements are maintained over time^[2]

This follow-up study will involve regular check-ups and hearing tests for participants who received AAVAnc80-hOTOF in the initial clinical trial.

AAVAnc80-hOTOF represents an exciting potential breakthrough for people with otoferlin-mediated hearing loss. While it’s still in the testing phase, this gene therapy offers hope for a future where this type of genetic hearing loss could be treated effectively.

Table of Contents

• What is AAVAnc80-5’HOTOF?
• How does it work?
• What condition does it treat?
• Clinical Trials
• Administration
• Eligibility
• Safety and Efficacy
• Long-Term Follow-Up

What is AAVAnc80-5’HOTOF?

AAVAnc80-5’HOTOF is an innovative gene therapy medication being developed to treat a specific type of hearing loss. It is part of a treatment called AAVAnc80-hOTOF, which consists of two components: AAVAnc80-5’HOTOF and AAVAnc80-3’HOTOF^[1]. This therapy is currently being studied in clinical trials to evaluate its safety and effectiveness.

How does it work?

AAVAnc80-hOTOF is a gene therapy that uses a special type of virus called AAV (adeno-associated virus) to deliver a healthy copy of the otoferlin gene (OTOF) to the inner ear. The therapy is designed to replace the faulty gene that causes hearing loss in some people^[1].

The treatment uses a “dual vector approach”, which means it uses two separate components (AAVAnc80-5’HOTOF and AAVAnc80-3’HOTOF) to deliver the complete gene. This is necessary because the OTOF gene is too large to fit into a single AAV vector^[1].

What condition does it treat?

AAVAnc80-hOTOF is being developed to treat otoferlin gene-mediated hearing loss. This is a type of sensorineural hearing loss caused by mutations in the otoferlin gene^[1]. People with this condition typically have profound hearing loss from birth, which means they have very little or no hearing ability.

Clinical Trials

The treatment is currently being studied in clinical trials to determine its safety and effectiveness. There are two main studies:

1. A Phase 1/2 trial (study number 2023-505128-76-00) that aims to assess the safety, tolerability, and initial effectiveness of AAVAnc80-hOTOF^[1].
2. A long-term follow-up study (study number 2024-512584-31-00) to evaluate the long-term safety and efficacy of the treatment^[2].

Administration

AAVAnc80-hOTOF is administered through a procedure called intracochlear administration. This means the medication is delivered directly into the cochlea, which is part of the inner ear^[1]. The procedure is performed by a healthcare professional using a special delivery device.

Eligibility

The clinical trials have specific criteria for who can participate. Some key eligibility factors include:

• Age: Participants must be between 2 and 17 years old at the time of treatment^[1].
• Genetic confirmation: Participants must have confirmed mutations in both copies of their OTOF gene^[1].
• Hearing loss severity: Participants must have profound bilateral sensorineural hearing loss^[1].
• Preserved outer hair cell function: This is assessed through a test called otoacoustic emissions (OAEs)^[1].

Safety and Efficacy

The main goals of the clinical trials are to assess the safety and effectiveness of AAVAnc80-hOTOF. Researchers are looking at:

• The frequency and types of side effects (adverse events) related to the treatment^[1].
• Changes in hearing ability, measured through various hearing tests^[1][2].
• Improvements in speech recognition and other hearing-related abilities^[2].

Long-Term Follow-Up

Participants who receive AAVAnc80-hOTOF in the initial trial will be invited to participate in a long-term follow-up study. This study aims to monitor the safety and effectiveness of the treatment over an extended period^[2]. This is important because gene therapies can have long-lasting effects, and it’s crucial to understand both the benefits and any potential risks over time.

In conclusion, AAVAnc80-5’HOTOF, as part of the AAVAnc80-hOTOF gene therapy, represents a promising approach to treating otoferlin gene-mediated hearing loss. While still in the clinical trial phase, this innovative treatment offers hope for individuals with this rare form of genetic hearing loss. As research continues, we will learn more about its safety, effectiveness, and long-term outcomes.

Table of Contents

• Trials overview
• Study design and groups
• Who can participate
• What the trials measure
• Trial status and size
• What this means for patients

Trials overview

Two interventional trials are studying 2,4 DICHLOROBENZYL ALCOHOL in lozenges for people with acute pharyngitis, which means a sudden sore throat.^[1][2]

Both studies are designed to check whether the lozenges help with symptoms and whether they are safe in this setting.^[1][2]

Study design and groups

Each trial is a Phase 3, prospective, randomised, multi-centre, double-blind, placebo-controlled study.^[1][2]

Randomised means people are assigned to groups by chance, and double-blind means neither the patient nor the study team knows which treatment is being given during the trial.^[1][2]

The studies compare the test lozenges with a placebo and with an active comparator, which is another treatment used as a reference.^[1][2]

The brief summary says the goal is to test non-inferiority against the active comparator and superiority against placebo.^[1][2]

Who can participate

The target population is patients with acute pharyngitis.^[1][2]

The source data do not list age limits, sex limits, or other detailed entry rules, so the main known requirement is having the condition being studied.^[1][2]

What the trials measure

The primary outcome is the change in Throat Soreness Intensity Scale (TSS) from baseline over the first 2 hours after the first application on Day 0.^[1][2]

The trials use area under the curve (AUC), which is a way to add up symptom changes over time and show the total effect during the 2-hour period.^[1][2]

In simple terms, the study is asking whether the lozenges reduce throat soreness better than placebo and whether they perform as well as the reference treatment.^[1][2]

Trial status and size

One trial is withdrawn, which means it did not continue as planned.^[1]

The other trial is authorised, which means it was allowed to proceed.^[2]

Each study planned to enroll 810 participants, so the combined planned enrollment was large for a symptom-relief study in acute pharyngitis.^[1][2]

What this means for patients

These trials focus on short-term relief of sore throat symptoms, not on long-term treatment of a chronic disease.^[1][2]

Because the studies are Phase 3 and compare the treatment with placebo and another active lozenge, they are meant to give stronger evidence about how well the product works in real patients with acute pharyngitis.^[1][2]

The available data are focused on symptom relief, study design, and trial status, and do not provide more detailed patient selection rules or extra outcome measures.^[1][2]

People in the study are placed into one of two groups. One group has the blood flow checked with indocyanine green fluorescence imaging, which means the dye is used so the surgeon can see how blood moves through the flap. The other group is checked with standard clinical assessment, which means the usual way of judging the flap during surgery. After the operation, the flap is followed for a short time to see how it heals and whether any further treatment is needed.